Today marks a defining moment in Canurta’s journey—our first Satoshi Trials™ loan, secured directly against our Bitcoin treasury, has closed. On May 13, 2025, we leveraged 0.34765 BTC as Collateral with APX Lending for a simple fixed-rate facility, showcasing our innovative R&D Strategy. These funds immediately kick-start our new R&D partnership with TransBioTech, where we’ll embark on a two-part preclinical program (toxicology and BBB penetration studies) for CNR-401, our lead adaptive-medicine candidate, for the treatment of ALS.

Why does this matter? By pledging Bitcoin—rather than diluting equity or mortgaging physical assets—we’ve unlocked capital in a matter of days. The APX process was seamless: no lengthy covenants, no appraisal delays, no board sign-offs on heavy equipment—just a swift drawdown that puts cash in our account when and where R&D demands it. Compare that to a traditional equipment or real-estate loan: paperwork meanders for weeks, if not months; covenants drag you into endless negotiations; and interest rates are often higher.

From here, our funding stack will blend:

• R&D tax credits to reimburse eligible research spend,

• Shareholder support via modest revenue‐share or royalty structures, and

• Bitcoin appreciation as an offset to financing costs.

Over the life of this loan, any appreciation in our BTC holdings directly reduces net borrowing costs—turning a liability into another potential value driver. More importantly, we’ll demonstrate that a Canadian biotech can sustainably leverage Bitcoin on its balance sheet to accelerate ALS research without excessive dilution and continued fundraising in dire funding climates.

To our investors, this transaction signals that Canurta is not just innovating in the lab, but innovating in finance. We’re building a blueprint where cutting-edge adaptive medicine is underwritten by best-in-class treasury management—bridging digital-asset finance with life-science impact. This is exactly the kind of agility our industry needs to outpace clinical timelines and deliver life-changing therapies.

We look forward to sharing data as our TransBioTech studies progress and showcasing how each preclinical milestone parallels growth in shareholder value. Thank you for your continued trust as we pioneer the Satoshi Trials™ model, fighting ALS and other complex diseases by marrying biotech rigor with Bitcoin’s financial power. We look forward to sharing our success on this journey and the results of the research as we continue from here.

Onward with focus and intention,

Akeem Gardner | CEO & Founder | Canurta Therapeutics

At Canurta, we’ve never followed convention for convention’s sake. We’re building a new blueprint for how biotech companies can scale — one that prioritizes financial resilience, founder-led execution, and long-term shareholder value. That’s why we’re anchoring our capital strategy to Bitcoin.

This is not a gimmick. It’s a deliberate financial move that increases our purchasing and R&D power by 30–60% ARR and positions us to lead institutional biotech innovation in Canada with asymmetric upside and limited downside. We're creating the first adaptive medicine company backed by Bitcoin reserves — and with it, a new playbook for the capital markets.

Why Bitcoin

Strengthens Capital Efficiency

By integrating Bitcoin into our treasury model:

• We gain exposure to an appreciating reserve asset

• We minimize dilution by accessing BTC-backed financing tools

• We enable strategic rebalancing to meet investor needs during volatility

Enables Optionality Without Fragility

With regulated Canadian OTC access and margin lending partners, we can:

• Sell or collateralize BTC as needed, without relying on banks

• Fund trials, operations, or acquisitions with non-dilutive capital

• Maintain a steady NAV anchor (3:1) to issue optional securities if desired

Aligns with Institutional Trends

With FASB guidance and growing institutional adoption, BTC is no longer fringe — it’s part of the future. This gives Canurta a chance to front-run a shift in capital formation and stand out as an institutional-grade biotech that operates with the prudence of a sovereign investor.

Rethinking Risk

As Warren Buffett said:

“Risk is not volatility, but permanent loss of capital.”

We agree. Volatility is not the enemy — poor execution is.

Bitcoin offers volatility, yes — but also resilience, transparency, and global liquidity. By contrast, the permanent loss of purchasing power in fiat currencies, especially the USD, is the silent risk that most overlook.

What It Takes to Win

Executing a strategy like this requires:

• Courage from the founder

• Goodwill from the team

• Trust from our investors

And most importantly: results. We're not asking to be believed — we're asking to be measured. Canurta’s team is here to execute.

The Broader Vision: Advancing Canadian Capital Markets

Our ambition goes beyond Canurta. We believe Canada can be a global leader in BTC-backed biotech finance. We're building this strategy not just for ourselves, but for:

• CanadianMunicipalities, like Vancouver, with forward-thinking financial structures

• Corporations and SMEs looking to access resilient, modern capital

• Boards of Trade and innovation councils who can champion resilient business models across the country

This isn’t theory — it’s a testable, repeatable path. One step at a time, using open-source tools, transparency, and results.

The “Holy Grail” of Finance: Uncorrelated Alpha

Bitcoin gives us what traditional portfolios struggle to find: An uncorrelated asset that improves risk-adjusted returns.

We manage volatility through:

• Position sizing and drawdown strategies

• Keeping our mind on long time horizons that allow us to ride macro cycles

• Quarterly rebalancing and capital rotation discipline

Closing Thought

Markets reward clarity and courage.We’re not chasing trends — we’re setting the terms.

BTC gives Canurta the freedom to execute without surrendering control. It strengthens our balance sheet, hedges systemic risk, and creates a durable advantage for our shareholders — one that compounds over time.

We're not here to play defense. We're here to win.

Let’s build the future of medicine — backed by the future of money.

Akeem Gardner | CEO & Founder | Canurta Therapeutics | akeem@canurta.com

Life has a unique way of guiding us exactly where we need to be, often without us fully realizing it at the time. My journey led me to study law at the University of Kent, Canterbury, a path seemingly unrelated to my core passion—innovation and entrepreneurship. Yet, it was precisely in my Company Law class in October 2015 where I first encountered the fascinating saga of the South Sea Bubble of 1720, an event that profoundly reshaped society and laid the foundation of the very legal principles that govern our world today.

The South Sea Company promised unimaginable riches from the transatlantic slave trade, exploiting collective enthusiasm and lack of transparency—hallmarks of many historical bubbles. Jonathan Swift's poignant verses captured the turmoil and despair that ensued, as fortunes were lost overnight:

What struck me deeply was how history, if not understood, inevitably repeats itself. It was clear to me then, as it is now, that awareness of foundational rules—how company law, equity, and property rights emerged from natural principles—remains essential. Without grasping these fundamentals, we cannot truly participate, let alone thrive, in the intricate game of society and commerce.

Yet, history also teaches optimism. Even after devastating crashes, markets recover and soar higher, driven by human ingenuity, innovation, and the foundational trust enabled by clear and enforceable laws. Institutions like the Royal Exchange and London Assurance survived the South Sea catastrophe because they created lasting value—value born from integrity, vision, and disciplined governance.

At Canurta Therapeutics, we find ourselves on the brink of another profound shift—the "digital state of nature," guided by transparency, decentralization, longevity, and trust. Understanding our origins gives us clarity in navigating these emerging trends. It informs our commitment to building something that matters, something resilient enough to weather future storms and purposeful enough to leave lasting impacts on all stakeholders.

Great companies endure because they commit to principles deeper than profit alone—they create enduring value, empower communities, and foster confidence for the long term. This is the path we choose at Canurta.

The universe led me to law school, not by chance, but to prepare me to recognize patterns, anticipate change, and build with foresight. As we embark on this exciting next chapter, I remain deeply inspired by history's lessons and energized by the limitless possibilities ahead.

With gratitude and purpose,

Akeem Gardner

On our Bitcoin node at Canurta, we recently verified something humbling — not on an explorer, but through the raw console, peering directly into the chain.

We traced Block 49, mined just days after the Genesis Block. It’s the last block seen by Hal Finney’s node before he reported a crash. It may even be the block his machine mined.

In it sits a coinbase reward of 50 BTC, untouched to this day — a still, silent reservoir of energy created in the network’s infancy. It hasn’t moved, but it echoes.

Just a few days later, at Block 170, that energy shifted.

Satoshi sent Hal the first Bitcoin transaction ever recorded. 10 BTC — peer to peer, human to human, intention to intention.

🧭 From Running the Client to Running the Future

For us at Canurta, these two blocks — 49 and 170 — are more than trivia.

They represent something sacred in the rhythm of innovation:

• 🟠 Block 49: the unknown moment you begin, when the node connects, the crash happens, but the effort is real.

• 🟢 Block 170: the moment the world responds, and something new is validated, on-chain and in life.

🧬 Proof of Purpose: Our Bitcoin Commitment

At Canurta, we’re building something equally foundational — a decentralized future for adaptive medicine, powered by science and protected by principles.

As we grow our treasury under the Satoshi Trials strategy, we’ve made a symbolic commitment:

🔐 We will dedicate the first 50 BTC we hold to Block 49 and Block 170.

They will sit at the heart of our digital balance sheet, not as an investment — but as a monument.

A reminder that energy doesn’t just power a chain. It can power a mission.

✨ To Builders, Dreamers, and Endurers

Hal’s node didn’t need fanfare. It didn’t need permission. It didn’t even work at first.

But it mattered.

And maybe the most meaningful parts of what we build — in life, in Bitcoin, in medicine — are not the ones that move first… but the ones that endure longest.

We honour that energy. We intend to carry it forward. We will use it to #FightALS.

-- Akeem Gardner

Founder & CEO, Canurta Therapeutics

#SatoshiTrials #Block49 #Block170 #ProofOfPurpose

Hal Finney helped start the chain.

When he tweeted “Running Bitcoin” in 2009, he did more than launch a network—he became its first human node. He mined the first blocks. He received the first transaction. And then, not long after, he received an ALS diagnosis.

But here’s the part that never leaves me: he kept going.

Even as his body weakened, Hal kept coding with speech‑to‑text software. He stayed plugged in. He called Bitcoin “an exciting possibility.” He kept contributing because each new block gave him purpose—a signal that his energy was still shaping the future.

And now, it is.

At Canurta, we will pioneer the Satoshi Trials™, using the power of Bitcoin in our Corporate Treasury to fund R&D. With every block, we’re moving closer to a world where we can show how nature can be harnessed as the best medicine. We’re translating block time into biological progress.

This isn’t metaphor. It’s design— with the deeper purpose to complete the loop: the same digital system that gave Hal hope will now help us fund and fuel ALS research. His energy—immortalized in the Bitcoin ledger—is powering a therapeutic frontier that could one day deliver on what he never got to see.

We believe in transparency. Like Bitcoin, our science will remain verifiable and open.

We believe in persistence. Like Bitcoin, our model compounds over time.

And we believe in decentralized resilience—because it will take more than one institution to solve ALS.

This ALS Awareness Month, we’re not just remembering Hal Finney.

We’re building with him.

One block at a time.

—Akeem Gardner

Today, I took a moment to verify Block 170—the first-ever recorded Bitcoin transaction—from our own Canurta Bitcoin node. It was a simple yet historic transfer of 10 BTC from Satoshi Nakamoto to Hal Finney, but its significance extends far beyond its numeric value.

Experiencing this directly, without intermediaries, felt like stepping into a new kind of wilderness—one governed by decentralization, transparency, and immutable truth. It took me back to my days at the University of Kent in Canterbury, where I first encountered the idea of the "state of nature". Historically, when humanity emerged from the wild, the rule of law was essential in building just societies capable of innovation and lasting prosperity.

Today, we find ourselves at the threshold of another "state of nature"—the digital state of nature. Just as human society once relied on law to guide and nurture civilization, this new digital world requires its own guiding principles. In the digital state of nature, decentralization, trustless verification, and incorruptible transparency must form the foundation upon which we build.

At Canurta, we are deliberately embracing this philosophical intersection of decentralization and biotechnology. By harnessing nature's profound innovations and coupling them with Bitcoin's decentralized principles, we forge a path that not only sustains our company but revolutionizes how innovation in human and animal health is financed and realized.

My undergraduate studies at the University of Ottawa in psychology and philosophy further shaped my perspective on how innovation, human behavior, and ethics intertwine. These disciplines taught me that sustainable innovation thrives best in an environment grounded in truth, transparency, and decentralized governance.

This is our unique commitment at Canurta—to unlock nature's power, guided by decentralized truth and verifiable digital energy, to fundamentally transform health outcomes.

We’re just getting started, but this is exactly the future we're ready to build.

— Akeem Gardner

CEO, Canurta Therapeutics

April 30, 2025

When I first began building Canurta, it was with the belief that nature holds solutions to some of our most complex human conditions — including neurodegenerative diseases like ALS. What I didn’t expect was how much I would come to see Bitcoin not just as digital money, but as a form of digital energy — and perhaps, even more importantly, as a protocol for resilience.

Today, I’m proud to share that we’ve set up and are running a full Bitcoin node at Canurta.

This might seem like a strange move for a biotechnology company. But for me, it’s a natural progression of what we believe in: decentralization, integrity, and energy that cannot be corrupted. Bitcoin isn’t just a network. It’s an architecture. And increasingly, I think it’s an architecture that science and medicine need.

We are working every day to build the Polykye Platform — our infrastructure for adaptive, botanical therapeutics. As we begin rolling out our Satoshi Trials program for ALS research, I want to be able to say that the work we do is grounded in more than theory — it’s anchored to something verifiable, distributed, and open.

Running a Bitcoin node is part of that commitment.

It allows us to:

• Independently verify and interact with the Bitcoin network

• Begin exploring tools like timestamping, decentralized registries, and protocol-native research documentation

• Bring the same integrity and transparency we demand in science into the systems that support it

For those who’ve followed Canurta’s journey, you already know we’re obsessed with the intersection of plant intelligence, human resilience, and decentralized systems. This is one of the first visible steps in a longer roadmap to bring blockchain technologies into the heart of scientific research — not for hype, but for coordination, accountability, and freedom.

This isn’t just about Bitcoin.

It’s about refusing to build tomorrow’s therapies on yesterday’s infrastructure.

More to come soon — on how we see Bitcoin’s architecture shaping the next generation of adaptive therapeutics, and why we believe this matters for people living with ALS.

For now, just know this:

The chain is syncing.

And the mission continues.

— Akeem

Founder & CEO, Canurta Therapeutics

"Want to Learn More?":

If you're curious about why running your own Bitcoin node matters—for decentralization, resilience, and security—these resources provide a great starting point:

• Fully Noded: The Basics and Benefits of Running a Bitcoin Node (Nasdaq)

• What is a Bitcoin Node? (Unchained)

• Why Should I Run a Bitcoin Node? (River Financial)

Special Note: The initial Bitcoin price considered for these calculations is $100,000 USD per BTC given we [had on Dec 15th, 2024] passed the psychological price benchmark.

Setting the Stage for Disruption

Biotechnology has long grappled with the high costs and uncertainty of drug development, leaving promising therapies for diseases like ALS underfunded. At Canurta, we recognize the need for a transformative approach—one that not only addresses these challenges but redefines how biotech innovation is funded.

The Satoshi Trials™ bring together the financial power of Bitcoin with the precision of adaptive medicine, creating a revolutionary framework for clinical research. By integrating financial technology into our funding strategy, we are not only accelerating ALS treatment but also laying the foundation for a resilient and scalable biotech model.

Navigating Financial Challenges for Strategic Growth

Traditional biotech funding models often rely heavily on dilutive equity raises and venture capital, which can limit long-term shareholder value. Canurta’s strategy disrupts this paradigm by leveraging Bitcoin’s growth potential as a dual-purpose asset: a secure treasury reserve and a catalyst for sustainable growth.

Through the Satoshi Trials™, Bitcoin reserves serve as collateral to fund clinical trials, while mining revenues create recurring income streams. This dual-engine model ensures Canurta has the financial strength to weather volatility, invest in R&D, and deliver exceptional value to our shareholders.

Vision 2035: Polykye™ and the Satoshi Trials™ (Bitcoin-Backed Clinical Trials)

By 2035, Canurta envisions a future where adaptive medicine has transformed not only how we treat diseases like ALS but also how we finance medical innovation. With the Polykye™ Platform at the forefront, our mission is to unlock the potential of nature-inspired molecules using advanced AI, delivering life-changing therapies faster and more efficiently than ever before.

Central to this vision are the Satoshi Trials™, a groundbreaking strategy that fuses Bitcoin’s unmatched growth potential with the life sciences. Through the strategic acquisition of Bitcoin, Canurta is building a treasury that fuels research while providing long-term financial stability. This approach allows us to redefine clinical trial funding—moving beyond traditional equity raises to a model that amplifies returns for shareholders.

We are not just conducting trials; we are creating a blueprint for a self-sustaining biotech enterprise. By leveraging Bitcoin-backed reserves and mining revenues, Canurta ensures that every milestone reached in the lab is mirrored by growth in shareholder value. Our financial strategy is designed to grow Canurta’s shareholder value significantly by 2030, with further upside as Bitcoin continues to appreciate.

This is more than a vision—it’s a roadmap to transforming how the biotech industry operates. With Bitcoin as our catalyst, adaptive medicine as our focus, and innovation as our driving force, Canurta is shaping a future where science and finance converge to achieve the extraordinary.

Bitcoin as the Catalyst for the Satoshi Trials™

Bitcoin-Driven Growth Strategy

At its core, Bitcoin is more than just a financial tool —it is a catalyst for innovation and a foundation for growth. Its decentralized nature and historical performance, with a base-case projected CAGR of 29%, make it an ideal asset for Canurta’s dual-engine strategy: leveraging Bitcoin as both a treasury reserve and a source of recurring income through mining.

The Satoshi Trials™ position Bitcoin as a transformative force in biotech financing. By integrating Bitcoin into our financial strategy, Canurta creates a resilient foundation that supports adaptive medicine development while providing unmatched value to shareholders. As Bitcoin grows in value, so does our ability to fund clinical trials, advance preclinical assets, and explore new frontiers in healthcare innovation.

Through fair value accounting, Canurta will bring transparency and stability to Bitcoin reserves, ensuring investors have a clear view of their growth. This forward-thinking approach aligns with the anticipated FASB and IFRS standards, demonstrating our commitment to innovation in both finance and science.

Initial Investment & Satoshi Trials™: To bring this vision to fruition, Canurta proposes allocating up to $34M USD into Bitcoin-Backed Clinical Trials, leveraging the transformative Satoshi Trials™ approach. This innovative strategy enables us to amplify the impact of our initial BTC investment by using it as collateral to secure additional Bitcoin exposure while simultaneously accessing liquidity to fund clinical trials. This dual benefit allows Canurta to accumulate appreciating assets and deploy operational capital.

Biotechnology Risk Mitigation: A New Paradigm

The high failure rate of drug development presents a substantial risk for any biotech company. By incorporating Bitcoin into its treasury strategy, Canurta diversifies its financial assets beyond traditional fiat reserves, which are vulnerable to inflation and devaluation. Clinical trials often span years, and Bitcoin’s unique potential for long-term appreciation during that same period provides an effective hedge against inflation and volatile capital markets. This strategic diversification is vital for Canurta, ensuring a steady and resilient stream of capital to fund the extensive R&D projects needed to drive transformative advancements in biotechnology.

Hedging Against Economic Uncertainty: Biotechnology is a capital-intensive field where financial uncertainty can often delay or derail critical research. To address these challenges, Canurta leverages Bitcoin as a hedge against economic volatility. Its decentralized nature, finite supply, and historical resilience position Bitcoin as an ideal asset for maintaining financial stability in even the most uncertain market conditions.

Over the past decade, Bitcoin has delivered consistent long-term growth, with a projected base-case CAGR of 29%. This growth trajectory enables Canurta to build a robust treasury reserve that not only funds clinical trials but also protects against potential downturns in traditional capital markets. By aligning Bitcoin’s growth with our operational strategy, Canurta ensures uninterrupted research and development, advancing the fight against ALS while safeguarding shareholder value.

Collateral for Loans: Bitcoin’s unique liquidity and accessibility allow Canurta to use its BTC reserves as collateral for operational funding, minimizing reliance on dilutive equity raises

• A 30% drop in Bitcoin price (from $100,000 USD to $70,000 USD) would raise the loan-to-value (LTV) ratio to 71.4%, requiring an additional $1.62M USD in collateral. • Canurta maintains sufficient cash reserves to mitigate such scenarios, ensuring that trials proceed without interruption.

This approach combines the stability of Bitcoin-backed financing with proactive risk management, creating a financial framework that supports transformative research while protecting shareholder interests.

Transforming Risk into Opportunity with Satoshi Trials™ Implementation

The Satoshi Trials™ represent a revolutionary framework for funding clinical research. By strategically leveraging Bitcoin as a treasury reserve and collateral asset, Canurta is transforming the traditional biotech funding model into a self-sustaining engine for growth.

Each trial within the Satoshi Trials™ framework follows these key steps:

1. Bitcoin Acquisition: Allocate $4.22M USD at $100,000/BTC to each countries clinical trial for CNR-401. This Bitcoin reserve becomes the financial backbone for clinical operations.

2. Collateralized Liquidity: Use the BTC holdings as collateral to secure operational funding, ensuring uninterrupted research and development.

3. Trial Execution and Milestone Alignment: Conduct trials across the United States, Australia, Canada, and the United Kingdom, achieving key clinical milestones that align with shareholder value creation.

4. Long-Term Reserve Growth: Retain BTC reserves as they appreciate, creating a financial foundation for future clinical programs.

This strategy not only funds ALS research but also establishes a scalable model for future adaptive medicine initiatives. The alignment of Bitcoin’s growth with clinical success ensures that Canurta delivers on its dual promise of advancing science and creating wealth for shareholders.

Transformative Impact of Bitcoin Integration

Unlocking New Financing Models

Public and Private Markets: Canurta’s Bitcoin strategy positions it as a pioneer at the intersection of biotechnology and financial innovation. By combining cutting-edge research with the transformative potential of Bitcoin, Canurta is setting a new standard for the industry.

By aligning Bitcoin’s growth with biotech milestones, Canurta is not just securing its future in adaptive medicine—it’s redefining what it means to lead in the public markets. A precedent for this approach can be seen in the case of MicroStrategy and other Bitcoin Standard Companies.

This strategy also offers a unique opportunity to attract institutional investors who are unable to hold Bitcoin directly but seek exposure through equities, including ETFs. By adopting this forward-thinking treasury model, Canurta aligns itself with cutting-edge financial practices that resonate with modern investment portfolios.

Institutional Investments: Building relationships with institutional investors fosters long-term growth partnerships that go beyond capital infusion. These partnerships provide Canurta with access to favorable financing terms and invaluable expertise in asset management and financial integration. By aligning with institutions that value innovative financial strategies, Canurta strengthens its financial resilience while positioning itself for sustained growth in both the biotechnology and investment landscapes.

Building a Resilient Foundation for Long Term R&D

Securing Leadership in Public Markets

Once Canurta transitions to public markets, its Bitcoin reserve will serve as a powerful catalyst for growth and investor confidence:

Enhance valuation: A strategically managed Bitcoin reserve showcases Canurta’s innovative financial approach, signalling foresight and leadership in leveraging cutting-edge strategies. Public market investors value companies that combine tangible financial assets with visionary growth strategies. This reserve not only strengthens Canurta’s financial foundation but also positions the company as a forward-thinking leader in both biotechnology and financial innovation.

Strengthening the balance sheet: Bitcoin integration fortifies Canurta’s balance sheet by providing a resilient hedge against economic volatility while demonstrating sound financial stewardship. The appreciation of Bitcoin’s value, coupled with Canurta’s strategic leveraging of BTC holdings, creates a robust financial foundation that bolsters the company’s market position. This approach reassures shareholders, instilling confidence in Canurta’s long-term stability and growth potential.

Capitalizing on the Bitcoin Opportunity

The timing of Canurta's Bitcoin Treasury Reserve strategy is uniquely advantageous. We stand at a pivotal moment in Bitcoin's growth cycle, highlighted by historical data tracking its value progression across halving cycles. The upcoming 2025 halving is projected to catalyze significant value appreciation, following the established trend of substantial price increases after previous halvings. This strategic entry point positions Canurta to capitalize on the anticipated upward momentum in Bitcoin’s value, aligning perfectly with our long-term financial and operational goals.

The Bitcoin Act of 2024, recently introduced in the U.S., marks a pivotal step in facilitating the adoption of Bitcoin as a treasury reserve asset for corporations. This legislative milestone underscores a growing institutional acceptance of Bitcoin and aligns seamlessly with Canurta’s strategy to leverage Bitcoin for both growth and financial resilience. By recognizing Bitcoin's utility in treasury management, the U.S. government has provided a regulatory foundation that reduces risk, ensures compliance, and instills greater confidence among stakeholders.

"The Bitcoin Act of 2024 is set to encourage U.S.-based companies to adopt Bitcoin as a reserve asset, recognizing its potential to safeguard against inflation and provide liquidity in an unpredictable financial landscape." (U.S. Senate Bill 4912)

This convergence of Bitcoin’s projected growth trajectory, increasing institutional adoption, and supportive government policy creates a rare and timely opportunity for Canurta to capitalize on Bitcoin’s next growth cycle. With legislation paving the way for wider acceptance and utility, Canurta is uniquely positioned to lead this transformative financial shift.

Fair Value Accounting and Financial Transparency

Bitcoin’s role in Canurta’s financial strategy extends beyond its growth potential—it serves as a cornerstone for transparency and innovation. The introduction of the FASB Accounting for Disclosure of Crypto Assets rule changes in December 2024, which allow fair value accounting for crypto assets, marks a pivotal moment for companies integrating Bitcoin into their operations. These changes, coupled with the anticipated alignment of IFRS 13, position Canurta as a leader in financial clarity.

Under fair value accounting, Canurta will report the market value of its Bitcoin holdings on a quarterly basis, providing investors with a transparent view of treasury performance. This approach eliminates legacy accounting models that obscured Bitcoin’s true value, ensuring that shareholders can track the growth of Canurta’s reserves alongside clinical milestones.

Anticipated IFRS alignment further strengthens Canurta’s position as a forward-thinking enterprise. By adhering to cutting-edge accounting standards, Canurta sets a new benchmark for financial innovation, aligning with global best practices while creating unmatched visibility for stakeholders.

Operational Execution: Diversified Funding and Risk Mitigation

Canurta’s strategy for financing clinical trials is built on precision, diversification, and risk management, ensuring financial stability even in volatile market conditions.

Diversification of Funds and R&D Credits

A cornerstone of this strategy is the disciplined allocation of funds, which are directed exclusively toward advancing clinical trials and R&D activities. This focus not only ensures alignment with Canurta’s mission-critical milestones but also unlocks additional financial advantages. By conducting clinical trials in jurisdictions like Australia, where R&D tax rebates of up to 43.5% are available, Canurta recoups a significant portion of its expenditures. These rebates provide a reliable cash inflow that offsets loan repayments, further reinforcing the sustainability of this strategy.

This dual-pronged approach—diversifying funds into R&D while leveraging tax incentives—creates a self-sustaining financial ecosystem. It minimizes reliance on speculative investments and external fundraising, ensuring operational continuity and advancing Canurta’s pipeline without diluting shareholder value.

Leveraging Bitcoin’s Long-Term Growth Potential

Bitcoin’s historical performance and modeled projections further solidify the viability of this strategy. Despite its short-term volatility, Bitcoin has demonstrated remarkable long-term growth, with annualized returns historically ranging between 60% and 100% over the past decade. Looking forward, the Bitcoin24 model projects a 21-year annualized growth rate (ARR) of 20.5% (Bear), 28.9% (Base), and 37.1% (Bull), positioning Bitcoin as a high-performing asset even under conservative scenarios. This robust historical track record and forward-looking projections reinforce Canurta’s strategic use of Bitcoin as a treasury reserve, enhancing the company’s financial resilience, operational stability, and ability to weather the challenges of biotech R&D.

Stress-Tested Risk Management

Canurta has prepared for adverse market conditions through extensive stress testing, ensuring the company’s financial position remains secure in a range of scenarios. Even in extreme cases, such as a 70% drop in Bitcoin’s value, Canurta’s BTC reserves are structured to withstand such volatility, with long-term value recovery anticipated. For example, a 30% price decline—from $100,000 USD to $70,000 USD—would increase the Loan-to-Value (LTV) ratio to 71.4%, requiring an additional $1.62 million USD in collateral to maintain loan terms. In more severe scenarios, such as a 50% price drop, the LTV would reach 100%, necessitating an additional $4.22 million USD in collateral. By maintaining sufficient cash reserves upfront, Canurta ensures uninterrupted operations and retains the flexibility to capitalize on market opportunities, such as acquiring additional Bitcoin at reduced prices during market downturns.

This disciplined approach to collateral management protects Canurta’s financial stability, ensuring that clinical operations proceed without interruption even in volatile market conditions.

The Living Hedge: Bitcoin as a Dynamic Safety Net for Investors

Beyond operational benefits, Canurta’s Bitcoin treasury serves as a dynamic catalyst for growth and innovation. By leveraging Bitcoin’s long-term appreciation potential alongside its liquidity, Canurta creates a self-sustaining financial model that strengthens the company’s position. This strategy not only amplifies returns through double leverage—using Bitcoin reserves to secure funding while retaining the asset’s upside—but also positions Canurta as a pioneer in financial resilience. Unlike traditional biotech investments, where risk is concentrated, Canurta’s Bitcoin holdings provide an added layer of strategic flexibility, empowering the company to weather challenges and capitalize on market opportunities from a position of strength.

The Bitcoin-Biotech Standard

This moment represents a rare and transformative opportunity to reshape not only how we fight ALS but also how we finance the future of medicine. Canurta’s visionary integration of adaptive medicine with the Satoshi Trials™ represents an unprecedented convergence of innovation, resilience, and strategic foresight. It is a bold and disruptive step toward tackling one of the most challenging diseases of our time while pioneering a revolutionary financial framework for biotechnology.

Our Bitcoin Treasury Reserve Thesis is not merely a funding mechanism—it is a redefinition of how biotechnology companies can sustain, scale, and thrive. By leveraging Bitcoin as a treasury asset, Canurta mitigates the limitations of traditional funding models, creating a self-sustaining financial engine that supports continuous R&D, ensures stability amid volatility, and positions the company at the forefront of financial and scientific innovation. This strategy exemplifies the values of adaptability and perseverance that inspired Bitcoin's inception and align seamlessly with Canurta’s mission to advance science and improve lives.

Bitcoin’s role within Canurta’s strategy extends far beyond its monetary value. It becomes the foundation of a sustainable financial model that fuels revolutionary science, adapts to global challenges, and delivers transformative change. By harnessing this dual force, Canurta is setting a new standard for how the life sciences industry approaches financial and clinical challenges, ensuring that cutting-edge research has the resources to thrive.

Institutional partners now have the opportunity to stand at the vanguard of this transformation. By supporting Canurta’s strategy, they join a journey that not only redefines biotech financing but also drives breakthroughs in adaptive medicine, offering hope and better outcomes for patients and families affected by ALS. Together, we can honor the visionary legacy of pioneers like Hal Finney, embrace bold ambitions, and deliver life-changing solutions. With your partnership, Canurta will turn today’s vision into tomorrow’s reality and work relentlessly toward a future where ALS is no longer a life sentence.

Contact Us:

Akeem Gardner | CEO & Founder | Canurta Therapeutics | akeem@canurta.com | akeem@canurta.com.au

References

[i] Canurta Platform

[ii] Effect of Cannflavins on Mitigating a Motor Neuron Disease - Akeem Gardner, LLB

[iii] Can the Fed’s rate cut change biotech’s ‘new normal’?

[iv] Bitcoin Whitepaper

[v] Bitcoin Returns vs Major Asset Classes

[vi] Crypto vs Gold

[vii] Bitcoin 24 Open-Source Model. Original contributors: Michael J. Saylor, Shirish Jajodia, Chaitanya Jain (CJ)

[viii] This is an initial allocation and Canurta’s Governance Body reserves the right to change this number to a more or less allocation of BTC over the life of the corporation.

[ix] B2X Loans

[x] Bitcoin 24 Open-Source Model. Original contributors: Michael J. Saylor, Shirish Jajodia, Chaitanya Jain (CJ)

[xi] Approval success rates of drug candidates based on target, action, modality, application, and their combinations

[xii] Fiat Money vs Commodity Money: Which is more Prone to Inflation?

[xiii] Why corporate foresight matters according to research

[xiv] The 2024 Bitcoin Halving: Analyzing Past Trends to Predict the Next Big Crypto Surge

[xv] S.4912 – BITCOIN Act of 2024

[xvi] Intangibles—Goodwill and Other—Crypto Assets (Subtopic 350-60)

[xvii] IFRS 13 - Fair Value Measurement

Attracted by the community, the apes, the roadmap but also their mission to support Alzheimer’s research, I, as an enterprising CEO, eagerly joined the Elderly Apes Retirement Club (EARC) where, as a budding biotech with novel molecules that hold neuroprotective qualities, knew we could add value.

On April 14th, 2022 the EARC will run a donation matching campaign with the American Alzheimer’s Society with the goal of giving away $100,000.00 to help #EndAlz. Today, we also want to share, that on behalf of the community, and Elderly Ape #888, our company will be pledging to investigate our novel hemp flavonoids and their potential as a neuroprotective agent to aid in the global fight to #EndAlz, whether as a natural supplement or drug.

A brief summary of why we’re excited about our flavonoids and Alzheimer’s:

We know that cannabis comprises an exclusive subset of prenylated flavonoids, the cannflavins (1). Based on peer-reviewed articles, we also know that cannflavins exhibit potent anti-inflammatory activity (2), and has a novel neuroprotective and anti-aggregatory effect relevant to Alzheimer’s disease (1). Furthermore, Shishtar et al. 2020 findings specified that a high flavonoid intake was associated with a lower risk of Alzheimer's and related dementias (3).

For the first time, there is a promising pathway towards making these novel compounds readily available on the market in their purity for humans, and our company, in association with our growing network of research partners at Canadian Universities and Research Colleges will be funding and supporting Alzheimer's preclinical trials, and publishing our findings on-chain and in academic journals, with acknowledgements to the community on behalf of EARC #888.

Our goal, by the time it's said and done, is to make this one of the most impactful peer-reviewed research articles to be submitted by an NFT #LFG 🚀

Looking forward to the world we have to do.

Together we will #HealTheWorld.

Akeem Gardner, EARC #888

For more information on our roadmap and scientific journey please reach out

akeem@canurta.com

If you’re interested in learning more about our molecules and our IP read our white paper below.

https://mirror.xyz/canurta.eth/SdS0mrpc_ZdY1BYElF_T-Cllj9LBa2btF_3QQy46bTA

Alzheimers References here:

(1) Eggers, C., Fujitani, M., Kato, R., & Smid, S. (2019). Novel cannabis flavonoid, cannflavin A displays both a hormetic and neuroprotective profile against amyloid β-mediated neurotoxicity in PC12 cells: Comparison with geranylated flavonoids, mimulone and diplacone. Biochemical pharmacology, 169, 113609. https://doi.org/10.1016/j.bcp.2019.08.011

(2) Rea, K. A., Casaretto, J. A., Al-Abdul-Wahid, M. S., Sukumaran, A., Geddes-McAlister, J., Rothstein, S. J., & Akhtar, T. A. (2019). Biosynthesis of cannflavins A and B from Cannabis sativa L. Phytochemistry, 164, 162–171. https://doi.org/10.1016/j.phytochem.2019.05.009

(3) Esra Shishtar, Gail T Rogers, Jeffrey B Blumberg, Rhoda Au, Paul F Jacques, Long-term dietary flavonoid intake and risk of Alzheimer disease and related dementias in the Framingham Offspring Cohort, The American Journal of Clinical Nutrition, Volume 112, Issue 2, August 2020, Pages 343–353, https://doi.org/10.1093/ajcn/nqaa079

                                                  \*\* \*\* \*\* \*\*

Chronic inflammation presents some of the most pervasive health challenges facing  the world today. Ischemic heart disease, stroke, cancer, diabetes, arthritis, fatty liver disease and both auto-immune and neurodegenerative conditions are only a few examples of common illnesses linked to inflammation. Worldwide, 3 of 5 people die due to chronic inflammatory diseases like stroke, chronic respiratory diseases, heart disorders, cancer, obesity, and diabetes (1).

Conventional treatments do not eliminate the source of inflammation and can be responsible for other ailments during or after treatment. These treatments typically involve the administration of nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, glucocorticoids and immunosuppressant  drugs, which are not ideal for everyone, can trigger addictions and include a range of side effects.

Advancements in research and development are pivotal in addressing the increasing  interest and urgent need for natural, alternative treatments to alleviate inflammation related diseases. Healthcare research, however, has often grappled with the challenges  of acquiring adequate funding which is usually subsidized in two ways: through  government funds and private investments.

While the former requires extensive time and resources coupled with high-failure  rates and competition rather than collaboration, the latter is often cited as being  a means of bias and personal gain. Combined, these barriers have compromised  progress towards a real solution.

With botanicals growing in popularity as an inflammation treatment, non-fungible  tokens (NFTs) are also being embraced as a new method of democratically funding  critical healthcare research and development. By pairing NFTs and healthcare  research, there is an exciting opportunity to explore novel, promising alternatives in a  modern, culturally relevant way that eliminates accessibility obstacles while remaining  autonomous, transparent and accountable.

Introducing The Healing Project

Canurta presents The Healing Project (THP), a collection of Utility NFTs that leverage IP and blockchain technology to advance the development of safe and natural solutions for chronic disease.

DeSci, or Decentralized Science, is the future of health discovery, allowing a diverse array of stakeholders to participate in clinical design, democratize product development and accelerate the build of a blockchain-enabled biotech organization.

The Healing Project will launch with five fractionalized NFTs, making up a total of 10,000 utility tokens on Ethereum blockchain.

Proceeds from the sale will not only advance research, but also facilitate the first-time commercialization of novel, patented (see Appendix 1), hemp polyphenols, including Cannflavins A  and B. These rare polyphenols are scientifically proven to be powerful anti-inflammatory molecules that have potential to rival synthetic anti-inflammatories shown to carry dangerous risk profiles that an overwhelming number of patients prefer not to take long-term.

This will improve treatment options (2) for those affected by chronic disease(s) and accelerate new research methodologies and innovation in botanical drug development.

THP incentivizes collective action by facilitating annual-donation opportunities that fund and guide charitable donations made by the Healing Project community. The community will collectively vote on the annual cause-of-choice donation generated from the sale of “with Canurta” products. In collaboration with emerging local artists, The Healing Project will continue to develop creative works and collections over the years with new sets of collectible NFT artworks and experiences.

The use of blockchain technology to host the project will permit transparent monitoring of project outcomes thereby serving as a measure and immutable record  of the THP member’s contributions to real world science and collective impact.

To learn more about NFTs, please see Appendix 2.

https://spatial.io/rooms/622fa7e1b9254e0001be9afb?share=5994436538526887

Join Our Community, Mint on Rarible for 0.0365 ETH

https://rarible.com/token/0xb2469a7dd9e154c97b99b33e88196f7024f2979e:31?tab=owners

Why Now?

• Accelerate fundraising and build of community-driven health systems

• Provides a new, DeSci, business model for research and development rooted in transparency and improved methodologies

• Ground breaking opportunity to solve chronic inflammation and inflammatory related diseases with novel, safe polyphenols

• Improved interactions between researchers, patient communities and analysis of research outcomes

How it Works

The Healing Project Package will contain five fractionalized 1/1 NFTs. The Community will own a total of 10,000 fractional pieces in the form of The Healing Project (THP) tokens. Each fraction is a utility and access token, advancing product development while providing token holders unique benefits.

Unique Community Benefits to THP Token Holders

Our community will tackle the isolating experience of chronic pain and disease in a fun and community-centric way. Calling on a diverse group of stakeholders, The Healing Project intends to catalyze people all around the world to come together on a mission to Heal the World.

THP token holders will benefit from:

Collaborator Communities With Canurta

Support hackathons and project sprints that will help equalize health care innovation across diverse communities.

Community Innovation Wallet

Help build blockchain based supply chains for rare botanical ingredients and their therapeutic discovery.

Continue to Build The Healing Project Story

Team Canurta have returned to earth transformed, with rare, powerful gifts from the giant spirits. How will they save their fellow humans and animals?

New Product Perks & Experiences

Early access to the products you help develop, while we build a new, positive manifesto for community-driven health discovery.

Guide Charitable Donations

Vote on the annual cause-of-choice donation for 1% of revenue generated from the sale of products With Canurta.

Platform Details

The Healing Project platform is built on various blockchain-related technologies.  The fractional-NFTs will be listed on Rarible and in the future will be connected to Canurta’s Blockchain for Canurta Supply Chain private-permission  blockchain through the Ethereum blockchain, which allows for exciting utility for token holders.

Rarible is an Ethereum based blockchain solution service that allows us to curate multiple NTFs with a variety of purposes. Fractional.art was used to fractionalize the five NFTs into 10,000 utility tokens.

Canurta will use a custom built private blockchain built using Hyperledger Iroha to manage the supply chain. Together with Ethereum’s blockchain technology, they create a historian for chained data to foster trust and integrity for its network participants and the general public.

Environmental, Social and Governance

Canurta is firmly anchored in our values including our commitment to ESG principles as  guided by our Sustainability Policy. These principles will be intrinsic to The Healing Project.

Funding Allocation

Funds acquired through the sale of NFTs will be allocated as follow:

Who is Canurta?

Canurta designs all-natural and innovative ingredients from hemp polyphenols to effectively support inflammation prevention and recovery. Our product innovation is accelerated by blockchain solutions and community-driven research.

Canurta’s mission is to solve the world’s biggest health challenge: preventing and managing chronic disease safely. We target inflammation because it is the root cause of disease. And we build natural solutions backed by science to rival synthetic anti-inflammatory ingredients that aren’t safe for daily or long-term support.

Apart from cannabinoids like CBD, the hemp plant contains over 400 bioactive compounds, including unique cannflavin-rich polyphenols that only Canurta can identify, optimize and capture. Cannflavins A and B are valuable due to their ability to eliminate inflammation at the source through dual inhibition of pro-inflammatory pathways.

Canurta connects proprietary technology with a leading network of researchers through a Decentralized Science or “DeSci” model to overcome the challenges of bringing rare, inflammation-fighting hemp polyphenols to market. We incentivize the development of safer, and more effective natural solutions while allowing communities of donors, scientists and patients to work together on clinical design and impactful healthcare discovery.

Canurta will launch its products in 2022, which will benefit from deeper investigation and an expanded supply chain through the sale of The Healing Project NFT.

https://mirror.xyz/canurta.eth/SdS0mrpc_ZdY1BYElF_T-Cllj9LBa2btF_3QQy46bTA

Science Advisory

Tariq Akhtar, Ph.D., Principal Investigator - Dr. Akhtar is a world-renowned plant biologist and has renowned expertise on polyphenolic molecules and their synthesis in the Cannabis Sativa plant. Dr. Akhtar is one of the inventors of Canurta’s extraction and biosynthesis platform patent. The biosynthesis platform produces novel and rare polyphenols with potent, natural therapeutic properties. Dr. Akhtar has ample expertise in plant biochemistry and metabolic engineering. His research focuses on better understanding plant specialized metabolism of compounds that are of economic relevance. He also works closely with collaborators in various fields such as organic chemistry, food science, neurobiology, and ecology, with the overall goal to shed light on the processes that operate at the interface of plant primary and secondary metabolism.

Dr. Neal Davies, Ph.D., Principal Investigator - Dr. Neal M. Davies directs the analytical method development and identification and characterization of major components found in our products while developing analytical methodology and validation of assays for cannflavins. He also leads the preclinical discovery of the therapeutic potential of our active ingredients for initial biopharmaceutical classification. Dr. Davies received his undergraduate degree in Pharmacy from the University of Alberta in 1991. In 1996, he completed his Ph.D. in pharmaceutical sciences, specializing in pharmacokinetics, at the University of Alberta.

Throughout his career, Dr. Davies has strived to maintain the highest standard of teaching and research, and his achievements in both areas have been recognized through numerous awards and honours including several from the United States Pharmacopeia and the Canadian Society of Pharmaceutical Sciences. He is active in numerous professional organizations/associations, including the Canadian Society of Pharmaceutical Sciences and the American Association of Pharmaceutical Scientists, and serves as a reviewer and on the editorial board of several pharmaceutical and pharmacological science journals.

Dr. Ethan Russo, M.D., Senior Medical Advisor - Dr.Ethan Russo advises and provides essential formulation expertise to the company’s natural product and drug development pipelines. Dr. Russo is a former president of the International Cannabinoid Research Society as well as a past chairman of the International Association for Cannabinoid Medicines. Dr. Russo is also a board-certified neurologist, a psychopharmacology researcher, and author of 50+ peer-reviewed journal articles and 7 books. Moreover, he is a preeminent global medical cannabis expert with over 24 years of clinical cannabis research experience, including his outstanding work at GW Pharmaceuticals as a study physician and medical monitor for Sativex® and Epidiolex® clinical trials.

To learn more about the rest of the Canurta team, please see Appendix 3.

Key Stakeholders

Project Creative Director

Jordan Sook is a mixed media contemporary artist from Toronto, Ontario. His art is inspired  by acts of imposition and alteration, recontextualizing elements within pop culture to create  new narratives. Jordan looks to change the landscape of Canadian art and broaden the  framework and understanding of Black art as a whole.

Jordan’s work ranges from acrylic paintings to sculptures and installations. His work invites us to view the world from a subjective innocence while exploring the relationship to the modern human complex relating to consumerism, economics and the social environment.

Jordan collaborated on The Healing Project artwork with VALMITR, a digital-driven, worldwide design studio that specializes in motion graphics and NFT collections creation.

Learn more about Jordan Sook

Conclusion

The Healing Project is an open and encouraging environment to innovate, share ideas and be rewarded no matter who you are. Our Token Holders will gain access to the DeSci Movement and join a community solving barriers to funding, research and transparent decision-making in the world of scientific discovery and health innovation.

The Healing Project community’s contributions will be recorded indefinitely on Canurta’s blockchain infrastructure, creating a truly collaborative approach to maximizing research applications towards natural solutions to fight inflammation and chronic disease, with a direct pathway to product development with transparent supply chain scale-up.

As such, Canurta remains fully accountable to a global, forward-thinking community, allowing for credibility and an ongoing culture of incentivizing the most important end-goals to promote longevity and a better quality of life for humans and animals alike.

For more information contact akeem@canurta.com or visit our website below. Buy your access token at Rarible.com and head to Discord to join our community today.

https://canurta.com/the-healing-project/

https://rarible.com/token/0xb2469a7dd9e154c97b99b33e88196f7024f2979e:31?tab=owners

Disclaimer: All rights for The Healing Project are granted and given under the GENERAL TERMS AND CONDITIONS FOR THE SALE OF HEALING PROJECT NON-FUNGIBLE TOKENs (NFTs).

Footnotes

1. ​​Pahwa R, Goyal A, Jialal I. Chronic Inflammation. [Updated 2021 Sep 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK493173/

2. See NFT Roadmap for Scientific Outcomes.

3. Payable annually beginning on June 30, 2023 for the prior financial year, and then annually each year thereafter.

Appendix 1: IP Summary

Appendix 2: What are NFTs?

Appendix 3: Canurta Team

Akeem Gardner, Founder & Chief Executive Officer - Akeem brings a unique  creativity and passion in creating the Canurta vision. Akeem is a true entrepreneurial thinker that uses his keen legal intelligence, through obtaining his L.L.B. from the University of Canterbury, to solve complex problems. As an innovative community  builder in niche markets, Akeem recognized the unlimited downstream potential hemp-based products. He has spent the last four years catalyzing himself as a leader in the cannabis/ hemp industry.

Pamela Kisun, Chief Operating Officer - Pamela oversees the company’s day-to-day administrative and operational functions and ensures strategic alignment  to long-term business objectives. She liaises with internal and external stakeholders and advises on corporate matters, including environmental, social and governance  principles. Pamela completed her Master’s Degree in Climate Change at the University of Waterloo with a focus on mitigation and adaptation measures. She has several years of experience in various positions, including research and analysis, policy advising,  project management and administration.

Shega Youngson, Chief Brand Officer - Shega leads the company’s brand development and is responsible for overseeing the planning, development and execution of our company's marketing and advertising initiatives including The Healing Project. Shega completed her Bachelor of Science (Hons) degree in Public Policy, Media and Graphic Communications at Rochester Institute of Technology. She is a leader in advocacy marketing, consumer engagement and brand strategy, with over 7 years of experience building marketing trends and launching new product experiences for leading cannabis brands and services, including Canopy Growth Corporation.

Cameron Parry, Production Quality Assurance Manager - Cameron Parry uses his knowledge and expertise to oversee the production of reliable products that consistently meet our standards and leads extraction optimization, purification and ingredient analysis. Cameron completed his Master’s Degree in Biotechnology at the University of Guelph and trained in metabolite extraction and analysis.

Ricardo Hewitt, Chief Technology Officer - Ricardo has been a pivotal asset in the development of Canurtas blockchain technology and NFT project. Ricardo obtained his Bachelor of Science (Hons) degree  in Computer Science from Ryerson University. He has over nine years of experience in software development with relevant positions, including B.S.A. at 4Pay and F.E.D. at  Rogers Telecommunications. Having completed I.B.M. Blockchain Essential and I.B.M. Blockchain Foundation Developer courses, Ricardo has been essential in architecting, designing, and coding version 1.0 of Canurta’s supply chain solution utilizing hyperledger fabric and I.B.M.'s resources.

Dominic Poku-Aidoo, Chief Information Officer - Dominic assists in making  all executive decisions regarding the technological interests of Canurta. Dominic obtained his Bachelor of Science (Hons)  degree in Computer Science from Ryerson University and has 8+ years of experience in various aspects of software programming, including work as a Digital Developer at Rogers Telecommunications. He is a strong  proponent of blockchain technology for impact magnification. He has been working diligently with Canurta to analyze code and software for proper integration of blockchain technology within the company’s operations; he has completed both the I.B.M. Blockchain Essentials and I.B.M. Blockchain Foundation Developer courses.

Kelly Boddington, Ph.D, Research Associate - Kelly provides scientific and technical expertise on research and development of a scalable platform for the synthesis of hemp-derived polyphenols. Kelly obtained her Ph.D. Biochemistry and Bachelor of Science with a concentration in Molecular Biology and Genetics  from the University of Guelph, provisioning expert insight into developing the company’s biosynthesis platform. She has published several articles highlighting her areas of expertise including the “Characterization of the Synthesis Pathway of Bioactive Compounds in Cannabis Sativa for the Biosynthetic Production of Novel Pharmaceuticals” which is directly related to her work with the company.

Eric Soubeyrand, Ph.D, Research Associate - Eric provides scientific and technical expertise on research and development of a scalable platform for the synthesis of  hemp-derived polyphenols. Eric is currently a Postdoctoral Research Associate at the  University of Guelph’s Molecular and Cellular Biology Department having completed his M.Sc. in Plant Biology and Biotechnology and Ph.D. in Plant Biology from the University  of Bordeaux (France). His skill set includes biochemistry, genetics and molecular biology, transcriptomics, cell biology and plant physiology and bio-imaging. His current research involves the quantification and identification of various metabolites found in Cannabis Sativa and molecular genetics, protein purification and metabolic chemistry to study and synthesize these molecules on behalf of the company.

Jordan Chin, Graphic Designer - Jordan Chin and executes creative requests for brand communications and marketing campaigns across multiple channels including print and digital platforms. He is responsible for managing creative briefs, expanding Canurta's brand identity, leading packaging design, overseeing a diverse workload and creatively supporting the launch of The Healing Project. He brings excellent design knowledge and communication skills to the marketing team. Jordan obtained his Bachelor’s in Industrial Design and minor in Psychology from Carleton University. He has 3 years of experience in Graphic Design.

Samantha Pallo, HR Coordinator - Samantha provides administrative support for the executive management team to ensure efficient operations. She is responsible for onboarding and processing new hires, preparing reports and presentations for internal and external communications, scheduling meetings and recording detailed minutes and carrying out various other record-keeping and data management activities. Samantha obtained her HR certification from Sheridan College, her MSc. in Occupational Environmental Safety and Health and BSc. in Biology with Minors in Environmental Biology and Marine Biology  from the University of the West Indies. She has  several years of experience in different roles, including HR and Administration.

Introduction

Canurta connects its proprietary technology with a leading network of researchers through a Decentralized Science or “DeSci” model to overcome the challenges of bringing rare, inflammation-fighting hemp polyphenols to market. We incentivize the development of safer and more effective natural solutions while allowing communities of donors, scientists and patients to work together on the clinical design and impactful healthcare discovery.

DeSci, is the future of health discovery, allowing diverse stakeholders to participate in the clinical design, democratize product development, and accelerate building a blockchain-enabled biotechnology organization. 

Why Now? 

• Accelerate fundraising and build of community-driven health systems

• Provides a new, DeSci, business model for research and development rooted in transparency and improved methodologies 

• Ground-breaking opportunity to solve chronic inflammation and inflammatory-related diseases with novel, safe polyphenols  

• Improved interactions between researchers, patient communities and analysis of research outcomes

In collaboration with Unstoppable Domains, Canurta provides the opportunity to build decentralized digital identities as a precursor to participation in Canurta’s supply chain and various communities.

Unstoppable Domains’ mission is to return the power of the internet to people. In order to accomplish this, they created NFT domains that allow you to control your digital data and identity. Your Unstoppable domain is your cryptocurrency address, your login to the decentralized web, and your universal username. Once your domain is purchased, it is yours forever; there are no renewal or additional fees, including minting and gas fees.

Moreover, a domain from Unstoppable Domains acts as a decentralized username. These blockchain domain names are linked to wallet addresses, making it easier to send and receive cryptocurrency payments, store digital assets, and create or browse decentralized websites.

Benefits of using an Unstoppable Domain

• Unstoppable Domains can be used to send, receive and store different cryptocurrencies. Lengthy and error-prone alphanumeric addresses no longer need to be memorized. They can all be accessed through a single domain name

• Digital payments are transparent, permissionless, borderless, and the users have complete control

• Unstoppable Domains (blockchain domains) are the foundation of Web3 because they are the gateway to the decentralized web

• In this decentralized ecosystem, users own and control their data and utilize these systems how they want

• Unstoppable Domains permits Humanity Check verification, a private identity layer that you can associate with your Unstoppable Domain

• Humanity Check verification only needs to be completed once per NFT domain

• Humanity Check proves you are a unique person to an application; this allows you to enrich your experience and collect rewards, all without revealing ANY personal information to that app, thus preserving your anonymity

How To Acquire and Setup an Unstoppable Domain?

Step 1:

On your browser, go to Contact | Canurta , then scroll to the bottom of the page and click on “Register a Web3 Domain here” (Figure 1).

Step 2:

A new tab will appear, taking you to Unstoppable Domains’ website; click on the “Sign Up/Login” tab to create an account (Figure 2, Figure 3).

Step 3:

Once you have successfully logged into the website, you can start searching for an Unstoppable domain of your choice. Once you type in your choice of prefix for the domain and hit enter, several “.extension” choices will appear (for example: .x or .crypto or .wallet, etc.) After choosing the option you like, hit the “Add to cart” tab (Figure 4).

Step 4:

You will be given several options to pay for the domain on the Checkout screen. Choose the one most convenient to you (Figure 5). 

Step 5:

Once the transaction is confirmed and successful, go to the “My Domains” tab to view your purchased domain (Figure 6).

Step 6:

Now, it's time to mint your domain!

*Why do I need to mint my domain? Minting is the process of registering a domain onto the blockchain via your crypto wallet to gain full custody of the domain you just got. This means that nobody else has control over it except you, the domain’s rightful owner. This is what makes the domain truly decentralized. Once minted, neither Unstoppable Domains nor any other entity will be able to make changes to the domain or take it back from you.

Click on the “Free Mint” button to mint your domain (Figure 7).

Step 7:

When you click on the “Free Mint” tab, a pop-up will appear, sharing some vital instructions for the minting process. Once you have read all the instructions, hit “Continue” to proceed further (Figure 8).

Step 8:

The minting process involves a few sub-steps. First, you need to connect to a crypto wallet. Choose your preferred cryptocurrency wallet.

• Click here to learn how to create a MetaMask Wallet account

• Click here to learn how to create a Coinbase Wallet account

• Click here to learn how to create a Trust Wallet account

For this example, we will be choosing MetaMask (Figure 9).

Step 9:

To establish a connection and verify the ownership of your account, confirm your email by clicking on the “Send Verification Code” tab (Figure 10).

You will receive a confirmation code in your email, enter the code and hit “Confirm” (Figure 11).

Step 10:

Choose the wallet address you wish to proceed with and confirm the transaction (Figure 12, Figure 13).

Step 11:

The minting has now begun. You can track the minting process (Figure 14).

Once you hit on the “Track Progress” tab, it will take you to the “My Transaction” page, showing you the transaction status (Figure 15).

Step 12:

Once the transaction is successful, hop on to the “My Domains” page. Here you will see your newly minted, truly decentralized and supercharged, literally unstoppable domain! (Figure 16).

FAQs

Will I be able to transfer my domain?

Yes. The domain is stored in your cryptocurrency wallet and can be transferred by you after you mint the name on the blockchain with your wallet.

Which cryptocurrencies will I be able to use with my domain?

Currently, Unstoppable Domains support over 281 cryptocurrency addresses to map to a domain name to make payments easier.

Will there be some sort of ‘Whois’ record with my personal information associated with my domain?

Not by default. Sharing ‘whois’ information is opted in i.e. something that you can choose to do if you want. Otherwise, your identity will not be publicly known.

How do payments work with my NFT domain?

Add your bitcoin, Ethereum, and Zilliqa addresses to your .zil or .crypto domain inside of the ‘my domains’ section at Unstoppable Domains . When someone types yourname.zil into a supporting wallet, the wallet looks up that domain on the blockchain finds the appropriate address, and sends it to the address associated with that name.

How Do Transactions Occur?

Transactions occur via Coinbase Wallet or Trust Wallet or your preferred cryptocurrency wallet.

You can learn more by visiting their respective websites.

How Do Taxes Work?

Canurta does not provide financial or tax advise. However, it is generally understood that when you withdraw or convert crypto to fiat, it will be taxed. There are generally two tax structures it falls under Capital Gains or Income Tax.

You can learn more about each one and what to expect here.

Will I Earn Interest on My Investment?

Although you would not earn interest directly through Coinbase Wallet or Trust Wallet, there are options to lend out your crypto and earn interest on decentralized finance (DeFi) apps.

You can learn more here.

Can Crypto Be Used Towards Big Purchases?

Traditional RRSPs give you the option to use your money for substantial purchases such as a down payment on a house or for education.

Many companies are adopting strategies to accept crypto payments for various purchases - including those who use it to buy and sell real estate. 

Is My Crypto Protected from Creditors?

This question would be best answered by asking your accountant and/or bank.

Are There Any Safeguards Against Volatility?

Unfortunately, your investment is subject to the ebbs and flows of the market.

Additional Resources

If you still have questions, you can always refer to the Coinbase Wallet, Trust Wallet and Unstoppable Domains help forums. 

1. Recitals. WHEREAS, Seller is a company specializing in novel polyphenols for therapeutic use and has a developing intellectual property portfolio that includes multiple production processes and use methods for hemp molecules; WHEREAS, Seller wishes to sell and assign to Buyer, and Buyer wishes to purchase and assume from Seller certain rights of Vendor to a set number of Ethereum-based non-fungible token(s) complying with the ERC-721 standard, ERC-1155 standard or other similar non-fungible token standard set out in the Ethereum blockchain contract (each an “NFT” and collectively the “NFTs”) representing artwork, community access and certain other utility associated with The Healing Project (the “Project”) through a Public Sale (as defined hereinafter) subject to the terms and conditions set forth herein;

   NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

2. Applicability. (a) These terms and conditions of sale (these "Terms") are the only terms which govern the sale of the NFTs by the Seller to the Buyer which shall also be named on the blockchain upon payment of the “buy now” purchase price or the “highest bid” price upon completion of the auction. Notwithstanding anything herein to the contrary, if a smart contract is entered into by both parties on the blockchain, covering the sale of the NFTs covered hereby, the terms and conditions of this Agreement shall prevail to the extent they are inconsistent with these Terms. (b) The accompanying Etherscan transaction confirmation (the "Sales Confirmation") and these Terms (collectively, this "Agreement") comprise the entire agreement between the parties, and supersede all prior or contemporaneous understandings, agreements, negotiations, representations and warranties, and communications, both written and oral. (c) Notwithstanding anything to the contrary contained in this Agreement, Seller may, from time to time change the Utility (as defined in Section 5) and delivery of such Utility associated with the NFTs without the consent of Buyer provided that such changes do not materially affect the nature or scope of the NFTs or the Utility included therein.

3. Transfer of NFTs. (a)The NFTs will be registered on the Ethereum (or any other) blockchain within a reasonable time after the receipt of Buyer's payment. Seller shall not be liable for any transaction fees, delays or loss in transit. (b) Seller shall use reasonable efforts to render the Utility specified hereunder as of the Sales Confirmation and a reasonable period of time thereafter.

4. Knowledge Agent Integration. The Seller retains exclusive ownership over the intellectual property (IP) underpinning the Knowledge Agent, a decentralized AI system designed to enable storytelling, character development, and collaborative narratives across the Xilas Syndicate universe. The Knowledge Agent supports the integration of characters, including Zyra, Mnemoros, Atroxys, and others, within the Syndicate’s overarching story while fostering innovation in decentralized storytelling and community engagement.

5. IP Scope for Knowledge Agent. The Knowledge Agent represents a proprietary system that leverages AI-driven narratives and blockchain technology to advance The Healing Project’s mission. This includes story frameworks, character arcs, and tools for decentralized community storytelling. All associated research, algorithms, and creative assets developed by the Knowledge Agent remain the property of the Seller.

6. Character Licensing for Knowledge Agent Usage. By owning the NFT, the Buyer acknowledges that their rights to interact with or use outputs generated by the Knowledge Agent (e.g., character-specific AI models, story scripts) are non-exclusive and limited to personal, non-commercial applications unless prior written approval is granted by the Seller.

7. NFT License. (a) Upon purchase of an NFT, the Seller shall grant to the Buyer a general NFT license (the “License”) that states the terms and conditions governing each NFT that is offered, sold, or transferred to any person (which may be an individual or an entity). If the Buyer sells, purchases, transfers, or acquires an NFT, the Buyer agrees to be bound by the terms of this License included herein. (b)The following definitions shall apply to this License: (i) “Art” means any art, design, drawing, fictional character, illustration, image, vector, video, 3D asset, template asset, or other pictorial or graphic work associated with the NFT. (ii) “Economic Activity” means any activity engaged in to obtain income, regardless of whether or not the activity is aimed at making a profit. (iii) “NFT” has the meaning ascribed thereto in the Recitals.

   (c) Intellectual Property Ownership: (i) Buyer shall own an NFT if the Buyer’s ownership of the NFT is cryptographically verified on the Ethereum blockchain. As an NFT owner, the Buyer owns the non-fungible token—i.e., the digital token recorded on the blockchain and the Art associated with the token. (ii) Buyer acknowledges that all intellectual property and proprietary rights in the research, studies, formulations and general concepts of the Project are owned by the Seller and any such elements included in any of the Utility associated with the NFT shall remain Seller property irrespective of the NFT transfer. (iii) Buyer does not have a right to use any trademarks or logos owned by Seller.

   (d) Buyer License (i) Once Buyer purchases an NFT, then Seller shall grant to Buyer a personal, non-sublicensable, non-exclusive, license to use, copy, display, modify, and create derivative works from the Art, subject to the limitations described herein. (ii) Transferring an NFT. Buyer may sell or transfer the Art associated with the NFT without approval from the Seller, and upon such sale or transfer, Buyer’s entire license to the Art and any associated rights will transfer to the new owner subject to the payment of the Royalty Fee (as defined in Section 9). The new owner will enjoy the license and any associated rights described in above, provided that the new owner’s ownership of the NFT is cryptographically verifiable on the Ethereum blockchain. Any transfer of the Utility associated with the NFT by the Buyer to a third-party shall require prior written consent of the Seller. (iii) Restrictions. You agree to not use the Art (A) in any way that is unlawful, pornographic, defamatory, abusive, harassing, obscene, libelous, harmful to minors, racist, sexist, homophobic, or otherwise objectionable to a reasonable person; or (B) in any way that would create any liability or risk to the Seller including by creating a conflict with its existing, service providers or partners which may result in an action being brought against the Seller by any third-party at the sole discretion of the Seller.

8. License for Collaborative Storytelling. The Buyer is granted a non-commercial license to use AI-generated story elements or character interactions derived from the Knowledge Agent for personal purposes. This license includes: (a) Sharing personalized character interactions on social media. (b) Engaging in discussions or derivative storytelling with other community members. (c) Accessing decentralized tools to co-create minor narrative contributions within the Xilas Syndicate framework.

9. Prohibition on AI Commercial Use. The Buyer may not use the Knowledge Agent’s outputs (including AI-driven story elements, character interactions, or world-building assets) for commercial purposes, nor create derivative works for profit, without explicit written consent from the Seller.

10. Utility. In addition to the License to the artwork, the Buyer will also receive the following Project utilities associated with the Project (each a “Utility” and together, the “Utilities”): (a) Priority access to Project findings from research and development on journals, articles, blockchain and other mediums to share information about clinical programs and findings with written acknowledgement of the Buyer’s support for the Project; (b) Ability to meet with Seller on certain matters related to the direction of the Project and research associated thereto including the selection of a “Cause of Choice” to receive 1% of annual profits from the Seller as of June 30, 2023 for the previous 365 calendar days. The “Cause-of-Choice” options provided shall be evaluated on a yearly basis, selected by the Buyer, and approved by the Seller using the Cantura Cause-of-Choice Framework; (c) Invitation of the Buyer to to participate in working groups of the Seller to participate, observe, ask questions and report to public the Project progress; (d) Early priority Whitelist access to any new projects by the Seller;

11. Integration with the Knowledge Agent. Ownership of the NFT grants the Buyer the right to participate in the broader Xilas Syndicate storytelling ecosystem through the Knowledge Agent. This includes: (a) Early Access to Stories: Priority access to new chapters, character arcs, or interactive narratives created by the Knowledge Agent, aligned with the Xilas Syndicate universe. (b) Community Participation: Invitations to collaborate in world-building exercises, contribute ideas for character development, or shape future storylines through decentralized decision-making platforms. (c) Customization of Characters: Limited options for personalized interactions with characters (e.g., Zyra) through the Knowledge Agent, enabling unique, story-driven engagements for the Buyer.

12. NFT Gated Knowledge Access. Owners will have exclusive access to the Knowledge Agent’s archive of decentralized narratives, character biographies, and research-backed storytelling tools, further immersing them in the Xilas Syndicate ecosystem.

13. Limitations and Exclusions: (a) Seller retains all rights and interest in all the underlying intellectual property. methodology and formulations related to the research, design and development of products associated with the Project or otherwise. (b) Seller retains the right to launch additional projects under the name “Healing Project” with new artwork every three (3) years from the date the NFT is transferred to the Buyer. Such new projects will focus on social mandates to benefit the global community at large. (c) The rights of the Buyer given at the point of purchase of the Project are non-fungible and cannot be awarded to another party except in accordance with Section 18.

14. Use of Proceeds. The proceeds from the sale of the NFTs will be used by the Seller to: (a) advance research and development activities of the Project. This may include, among other things, providing financial support to production, supply chain, logistics, clinical discovery and trials; and marketing to bring the Sellers products to market; and (b) publishing findings from clinical findings and research and development in journals, articles, blockchain or other mediums. (c) Other uses that benefit The Healing Project community.

    1. Funding Decentralized Storytelling. Proceeds from the NFT sale will partially fund the development and deployment of decentralized storytelling initiatives, including: (a) Expanding the Knowledge Agent’s capabilities to include additional characters and interactive tools; (b) Building blockchain-based platforms that enable community-driven decision-making and collaboration in shaping the Xilas Syndicate’s evolving narrative; (c) Research and development of AI-driven storytelling applications to enhance community engagement and participation.

15. Buyer's Acts or Omissions. If Seller's performance of its obligations under this Agreement is prevented or delayed by any act or omission of Buyer or its agents, consultants or employees, Seller shall not be deemed in breach of its obligations under this Agreement or otherwise liable for any costs, charges or losses sustained or incurred by Buyer, in each case, to the extent arising directly or indirectly from such prevention or delay.

16. Price. (a) All Prices are exclusive of all harmonized sales tax, goods and services tax, sales tax, value added tax, use and excise taxes, and any other similar taxes, duties and charges of any kind imposed by any Governmental Authority on any amounts payable by Buyer. Buyer shall be responsible for all such charges, costs and taxes; provided that, Buyer shall not be responsible for any taxes imposed on, or with respect to, Seller's income, revenues, gross receipts, personnel or real or personal property or other assets. (b) Any resale of NFTs will be subject to an automatic 10% royalty calculated on the total re-sale price and shall be awarded to Seller from the proceeds of sale received by Buyer as a royalty (the “Royalty”)

17. Payment Terms. (a) The Public Sale, if required, will be conducted through a reputable NFT marketplace, like www.opensea.com or equivalent.(b) The payment and following transfer of the NFTs will occur on the Ethereum blockchain with ownership of the NFTs registered on the blockchain and verified using the Ethereum Etherscan transaction record.

18. Warranty. SELLER MAKES NO CONDITION OR WARRANTY WHATSOEVER WITH RESPECT TO THE NFTS OR UTILITY, INCLUDING ANY (a) CONDITION OR WARRANTY OF FITNESS FOR A PARTICULAR PURPOSE; (b) CONDITION OR WARRANTY OF TITLE; or (c) WARRANTY AGAINST INFRINGEMENT OF INTELLECTUAL PROPERTY RIGHTS OF A THIRD PARTY; WHETHER EXPRESS OR IMPLIED BY LAW, COURSE OF DEALING, COURSE OF PERFORMANCE, USAGE OF TRADE OR OTHERWISE.

19. Limitation of Liability. (a) IN NO EVENT SHALL SELLER BE LIABLE FOR ANY CONSEQUENTIAL, INDIRECT, INCIDENTAL, SPECIAL, EXEMPLARY, OR PUNITIVE DAMAGES, LOST PROFITS OR REVENUES OR DIMINUTION IN VALUE, ARISING OUT OF OR RELATING TO ANY BREACH OF THESE TERMS, WHETHER OR NOT THE POSSIBILITY OF SUCH DAMAGES HAS BEEN DISCLOSED IN ADVANCE BY BUYER OR COULD HAVE BEEN REASONABLY FORESEEN BY BUYER, REGARDLESS OF THE LEGAL OR EQUITABLE THEORY (CONTRACT, TORT OR OTHERWISE) UPON WHICH THE CLAIM IS BASED, AND NOTWITHSTANDING THE FAILURE OF ANY AGREED OR OTHER REMEDY OF ITS ESSENTIAL PURPOSE. (b) IN NO EVENT SHALL SELLER'S AGGREGATE LIABILITY ARISING OUT OF OR RELATED TO THIS AGREEMENT, WHETHER ARISING OUT OF OR RELATED TO BREACH OF CONTRACT, TORT (INCLUDING NEGLIGENCE) OR OTHERWISE, EXCEED THE TOTAL OF THE AMOUNTS PAID TO SELLER FOR THE GOODS AND SERVICES SOLD HEREUNDER OR 100,000.00 CAD, WHICHEVER IS LESS. (c) The limitation of liability set forth in Section 12(b) shall not apply to (i) liability resulting from Seller's gross negligence or wilful misconduct and (ii) death or bodily injury resulting from Seller's acts or omissions.

20. Compliance with Law. Buyer shall comply with all applicable laws, regulations and ordinances. Buyer shall maintain in effect all the licenses, permissions, authorizations, consents and permits that it needs to carry out its obligations under this Agreement.

21. Termination. In addition to any remedies that may be provided under these Terms, Seller may terminate this Agreement with immediate effect upon written notice to Buyer, if Buyer: (a) fails to pay any amount when due under this Agreement; or (b) has not otherwise performed or complied with any of these Terms, in whole or in part.

22. Waiver. No waiver by Seller of any of the provisions of this Agreement is effective unless explicitly set forth in writing and signed by Seller. No failure to exercise, or delay in exercising, any right, remedy, power or privilege arising from this Agreement operates, or may be construed, as a waiver thereof. No single or partial exercise of any right, remedy, power or privilege hereunder precludes any other or further exercise thereof or the exercise of any other right, remedy, power or privilege.

23. Confidential Information. All non-public, confidential or proprietary information of Seller, including but not limited to, specifications, research findings, formulations, samples, patterns, designs, plans, drawings, documents, data, business operations, customer lists, pricing, discounts or rebates, disclosed by Seller to Buyer, whether disclosed orally or disclosed or accessed in written, electronic or other form or media, and whether or not marked, designated or otherwise identified as "confidential" in connection with this Agreement is confidential, solely for the use of performing this Agreement and may not be disclosed or copied unless authorized in advance by Seller in writing. Upon Seller's request, Buyer shall promptly return all documents and other materials received from Seller. Seller shall be entitled to injunctive relief for any violation of this Section. This Section does not apply to information that is: (a) in the public domain; (b) known to Buyer at the time of disclosure; or (c) rightfully obtained by Buyer on a non-confidential basis from a third party.

24. Force Majeure. No party shall be liable or responsible to the other party, nor be deemed to have defaulted under or breached this Agreement, for any failure or delay in fulfilling or performing any term of this Agreement (except for any obligations to make payments to the other party hereunder), when and to the extent such party's ("Impacted Party") failure or delay is caused by or results from the following force majeure events ("Force Majeure Event(s)"): (a) acts of God; (b) flood, tsunami, fire, earthquake, explosion; (c) epidemics, pandemics, including the 2019 novel coronavirus pandemic (COVID-19); (d) war, invasion, hostilities (whether war is declared or not), terrorist threats or acts, riot, or other civil unrest; (e) government order, law or actions; (f) national or regional emergency; (g) strikes, lockouts, labour stoppages or slowdowns, labour disputes, or other industrial disturbances; and (h) shortage of adequate power or telecommunications or transportation facilities; and (i) failure of any governmental or public authority to grant a necessary licence or consent. The Impacted Party shall give notice within five (5) days of the Force Majeure Event to the other party, stating the period of time the occurrence is expected to continue. The Impacted Party shall use diligent efforts to end the failure or delay and ensure the effects of such Force Majeure Event are minimized. The Impacted Party shall resume the performance of its obligations as soon as reasonably practicable after the removal of the cause. In the event that the Impacted Party's failure or delay remains uncured for a period of Sixty (60) consecutive days following written notice given by it under this Section 18, the other party may thereafter terminate this Agreement upon Five (5) days' written notice.

25. Assignment. Buyer may assign any of its rights to the Art associated with the NFTs through a resale of the NFTs without the Sellers consent. Buyer may only assign its rights in the Utility associated with the NFT or delegate any of its obligations under this Agreement with the Sellers prior written consent. Any other purported assignment or delegation in violation of this Section is null and void.

26. Relationship of the Parties. The relationship between the parties is that of independent contractors. Nothing contained in this Agreement shall be construed as creating any agency, partnership, joint venture or other form of joint enterprise, employment or fiduciary relationship between the parties, and neither party shall have authority to contract for or bind the other party in any manner whatsoever.

27. No Third-Party Beneficiaries. This Agreement is for the sole benefit of the parties hereto and their respective successors and permitted assigns and nothing herein, express or implied, is intended to or shall confer upon any other person or entity any legal or equitable right, benefit or remedy of any nature whatsoever under or by reason of these Terms.

28. Governing Law. All matters arising out of or relating to this Agreement are governed by and construed in accordance with the laws of the Province of Ontario and the federal laws of Canada applicable therein without giving effect to any choice or conflict of law provision or rule (whether of the Province of Ontario or any other jurisdiction) that would cause the application of the laws of any jurisdiction other than those of the Province of Ontario. The United Nations Convention on Contracts for the International Sale of Goods does not apply to this Agreement.

29. Choice of Forum. Any legal suit, action, litigation or proceeding of any kind whatsoever in any way arising out of, from or relating to this Agreement, including all exhibits, schedules, attachments, and appendices attached to this Agreement, and all contemplated transactions, shall be instituted in the courts of the Province of Ontario and each Party irrevocably submits to the non-exclusive jurisdiction of such courts in any such suit, action, litigation or proceeding. Service of process, summons, notice, or other document by mail to such Party's address set forth herein shall be effective service of process for any suit, action, litigation or other proceeding brought in any such court. Each Party agrees that a final judgment in any such suit, action, litigation, or proceeding is conclusive and may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by law. The Parties irrevocably and unconditionally waive any objection to the venue of any action or proceeding in such courts and irrevocably waive and agree not to plead or claim in any such court that any such action or proceeding brought in any such court has been brought in an inconvenient forum.

30. Notices. All notices, request, consents, claims, demands, waivers and other communications between the Seller and Buyer hereunder (each, a "Notice") shall be in writing and addressed to the parties at the addressed designated by the Buyer and if to the Seller to: hello@canurta.com with CC: akeem@canurta.com or by mail to 2425 Matheson Blvd. E, Suite 807, Mississauga, ON, Canada L4W 5K4. Notices sent in accordance with this Section will be deemed effectively given: (a) when received, if delivered by hand, with signed confirmation of receipt; (b) when received, if sent by a nationally recognized overnight courier, signature required; (c) when sent, if by facsimile or email if sent during the addressee's normal business hours, and on the next business day if sent after the addressee's normal business hours; and (d) on the seventh day after the date mailed by certified or registered mail by the Canada Post Corporation, return receipt requested, postage prepaid.

31. Severability. If any term or provision of this Agreement is invalid, illegal or unenforceable in any jurisdiction, such invalidity, illegality or unenforceability shall not affect any other term or provision of this Agreement or invalidate or render unenforceable such term or provision in any other jurisdiction.

32. Survival. Provisions of these Terms which by their nature should apply beyond their terms will remain in force after any termination or expiration of this Order including, but not limited to, the following provisions: Payment Terms, Compliance with Laws, Confidential Information, Governing Law, Choice of Forum and Survival.

33. Amendment and Modification. These Terms may only be amended or modified in a writing stating specifically that it amends these Terms and is signed by an authorized representative of each party.

Knowledge Agent Definition:

The Knowledge Agent is a proprietary AI-powered system owned by the Seller, designed to support interactive storytelling and character development within the Xilas Syndicate universe. It leverages decentralized technology to engage NFT holders, providing them with narrative tools and immersive experiences tied to The Healing Project and Xilas Syndicate’s mission.

10. Broad Narrative Scope:

The Knowledge Agent serves as the foundational AI system for characters within the Syndicate, enabling seamless integration of new characters like Mnemoros and Atroxys. Future updates will include tools for community members to propose new characters or plotlines, enhancing collective ownership of the story.

Originally published on September 28, 2021 in Canurta’s Journal

A quick note from Akeem before we begin:

“2021 was an amazing year. From the launch of our company we grew by acquiring additional IP and investors who are supporting our mission to heal the world with novel polyphenols that have never been clinically explored before. Our team has shown so much growth in our journey of discovery and learning, and it’s now time to implement our DeSci strategy for our company.

We begin with re-stating our original argument for Canurta as a company and laying out the case for why our ingredient portfolio of rare, hemp polyphenols is the perfect foundation to build a stand out blockchain-backed organization with end-to-end operations on-chain. We will complete the establishment of our digital twin mid-year as we look to modernize therapeutics and disrupt the way traditional Big Pharma operates — by leading with transparency, community support, and natural, safe, yet powerful molecules.

From here on out we will continue to publish all our findings, milestones and accomplishments, both clinical and corporate, on-chain through Mirror.xyz, so you can keep up with our mission-driven journey of discovery and meaningful growth in an open and transparent way.

So thank you again for taking this journey with us — now allow me to reintroduce Canurta’s White Paper.”

The Problem We Solve

Acute and chronic inflammation affects humans and animals regardless of age or lifestyle; inflammation can be physically and mentally detrimental by reducing quality of life. In fact, chronic inflammatory diseases have been recognized as the most significant cause of death in the world today, with more than 50% of all deaths being attributable to inflammation-related diseases such as ischemic heart disease, stroke,  cancer,  diabetes  mellitus,  chronic  kidney disease,  non-alcoholic fatty liver disease and auto-immune and neurodegenerative conditions (15). Despite the availability of conventional treatments, many have inherent adverse effects that compromise their benefits. Although there is a growing shift towards safer botanicals to alleviate these concerns, most alternatives are generally less effective, lack scientific validation, and are costly to produce.

To address these gaps, IP rights were developed for a number of production processes allowing Canurta to commercialize hemp-derived polyphenols, including prenylated flavonoids (Cannflavins A + B) and their related Bibenzyls (Canniprene), into numerous active ingredients. These molecules provide the potential for ground breaking therapeutic benefits due to their extremely potent anti-inflammatory activity and effectiveness through the dual inhibition of pro-inflammatory enzymes. However, given the scarcity of these novel molecules, they have never been formally assayed in animal or human models.

Based on the available evidence: what are the grounds for further investigation of these compounds, the molecule behaviours, and commercialization of novel and rare hemp polyphenols?

Analysis of Polyphenols and Hemp

Let food be thy medicine and medicine be thy food. – Hippocrates over 2000 years ago.

Polyphenols and flavonoids have been consumed by humans since antiquity (11). They are present in plant material, where they play a primary protective role in the face of environmental stressors. So, it is no surprise that when humans consume them in their diet, they induce protective enzyme systems that lead to good health (5, 8, 11). These molecules are nutrient-like, and have been claimed to be essential to humans in reaching our full “genetically-determined lifespan” (19).

Polyphenols are an unavoidable part of the human diet (4) with the most significant quantities consumed in wines, teas, fruit, fruit juices, and vegetables. The populations of the USA, Spain, Australia, and France are estimated to consume 190, 310, 450, and 550 mg of flavonoids every day, respectively—where a lack of polyphenols and related molecules may be the reason for high inflammatory and autoimmune conditions in Western society.

Much research has been done on polyphenols in general, which proves their potential as valuable molecules for promoting human health and wellness.

Studies have shown:

•   Short term benefits to brain function and neuro-protection and neuronal repair in the face of aging and insults; (4)

•   The ability to attenuate the inflammation oxidative stress implicated in the pathogenesis of cardiovascular disease and tumorigenesis and neuronal damage associated with neurodegenerative diseases and deterioration in cognitive function seen with ageing; (4)

•   Consumption inversely related to all aspects of cardiovascular health, including mortality; protection against cerebrovascular diseases and neurological disorders; including dementia; improved cognitive function in healthy middle age adults; and reduced cognitive impairment and cognitive decline in elderly populations; (4)

•   Epidemiological data from a cross-sectional study with 8335 subjects has shown that  flavonoids are inversely associated with plasma CRP 1 concentrations. Intake such as individual flavanols, anthocyanidin, and isoflavones was estimated from the United States Department of Agriculture, flavonoid databases; (8) and more.

These molecules are generally viewed as safer and express higher bioavailability, fewer side effects (5), and lower toxicity (10) than traditional drugs. No wonder they are of significant interest to researchers. As the top 3 countries engaged in polyphenol research, India, China, and the USA have generated almost 7000 published documents focusing on the relationship of phyto-chemicals and inflammation between 2000 and 2016 (10).

Though humans have consumed flavonoids since antiquity, knowing anecdotally that consuming fruits and vegetables are good for human health, we have only started to explore flavonoids within the last century of human existence. It was only in 1930 that the 'new substance rutin was isolated' from oranges, which, though first thought to be 'Vitamin P,' turned out to be a flavonoid (11). Since that time, more than 4000 flavonoids have been identified, including novel prenylated flavonoids, Cannflavin A & Cannflavin B.

In the mid-1980s, Barret et al. were able to show that these prenylated flavonoids have 30x more anti-inflammatory activity than aspirin without displaying toxicity (2). Cannflavins were shown to exhibit appropriate activity in the mouse writhing test for NSAIDs (3) while also inhibiting glutathione-dependent prostaglandin E synthase (PGE2) release from human rheumatoid synovial cells. Fast forward to 2014, Werz et al. were able to unequivocally show that cannflavins act as dual inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1) & 5-lipoxygenase (5-LO), two crucial enzymes in the biosynthesis of the pro-inflammatory mediators PGE2 and LTs respectively (7). Dual inhibition of mPGES-1 and 5-LO is considered a pharmacological strategy to intervene in inflammatory diseases and might be superior over single target interference in terms of efficacy and lower side effects.

The “mPGES-1 enzyme is a key player in inflammation, paresis, hyperalgesia and multiple diseases with inflammatory components including rheumatoid arthritis and osteoarthritis, periodontal, atherosclerosis, inflammatory kidney damage, stroke, multiple sclerosis and Alzheimer’s disease as summarized in several excellent reviews…It is strongly induced in inflamed tissues, over expressed in many tumors and unregulated under diverse pathological conditions, including osteoarthritis, inflammatory bowel disease, atherosclerosis, Alzheimer’s Disease, myocardial infarction and hepatitis.

Favorable modulation of PGE2 biosynthesis may provide a beneficial pharmacological strategy for intervention with respective diseases, with low risk of side effects that are usually associated with NSAIDs and COXs. Thus, drugs that target mPGES-1 are considered a valuable alternative to NSAIDs/COXIBs with improved selectivity and safety profile for treatment of diseases characterized by elevated PGE2 levels.” (17)

Surpassing Commercialization Barriers

Yet, despite the findings of the likes of Barrett, Werz, and more, there has yet to be a commercial application of cannflavins for consumer-facing products.

The reasons include:

•   They are minor constituents in hemp and challenging to obtain completely pure by isolation, and tend to co-crystallize with other phenolics, making their extraction process tedious and expensive; (7)

•   Pure polyphenols reportedly have decreased bioavailability and bioaccessibility; (5)

•   Despite promising pre-clinical research of cannflavins, translation to patient care is limited as the yield of the product through isolation techniques is often low, limiting the ability to produce enough compound for assessment in humans; (16)

But the market opportunity for a product that contains the benefits associated with these novel anti-inflammatory inhibitors is great.

Application to Canurta

Canurta’s mission is to leverage world-class expertise in plant biology, metabolic biochemistry, genetics and genomics, and analytical chemistry to overcome long standing barriers  to the commercialization of the prenylated flavonoids, cannflavins A & B (6). Canurta controls the IP and defensible technology that, for the first time, allows for the growth, extraction and biosynthesis of these polyphenolic compounds at commercial scales for human and animal health. These ingredients include powdered hemp polyphenol-rich ingredients, highly concentrated extracts, and pure, single polyphenols of interest. The feature molecules to highlight in our ingredient portfolio are cannflavin A & B, but other polyphenols of interest give Canurta its distinct advantage over other natural ingredient companies.

Evidence shows that pure polyphenols generally do not deliver the best bioavailability and bioaccessibility on their own. However, ingredients rich in a number of polyphenols show higher activity, which may be due to other active compounds that can establish synergistic functions (5). Canurta’s ingredient portfolio will include stand-alone pure cannflavins when we scale up our biosynthesis platform. Thus, there will be value in the other polyphenols, including the isoprenylated bibenzyl, canniprene (1). Canniprene is fascinating because it has been proven to outperform zileuton at suppressing 5-LO product formation (1), at a greater rate than cannflavin A or B. Werz et al. speculated that prenylation is essential for inhibition of mPGES-17– so the fact that canniprene and cannflavin are prenylated is cause for excitement when considering the natural synergistic effect they portray in our natural ingredients.

It has been clinically proven that repeated use of flavonoids leads to health benefits, as repeated use of anthocyanin extract from blueberries (300 mg/d for 3 weeks) significantly reduced the plasma concentration of NF-k B related pro-inflammatory cytokines and chemokine in a group of 120 men and women aged 40-70 (8). The repeated daily consumption of flavonoids in the North American diet bodes well for further consumer acceptance of prenylated flavonoids for therapeutic uses – and the health benefits and potential associated with the known activity of these novel molecules and how they operate are essential when examining the market potential. There are various product formats these ingredients can be integrated in. Canurta will be focused on entering the market as a high-activity anti-inflammatory ingredient for nutraceutical manufacturers, and all the necessary steps that are required thereof. But our research will work to optimize the propagation of polyphenols in our hemp biomass to an ideal ratio of consistently potent ingredients.

Risks

Though exciting, there are many challenges associated with polyphenols that Canurta will overcome in its clinical exploration, including unclear dosages, possible side effects, long-term toxicity, intricate interactions with pharmacological drugs, poor human evidence and clinical trials, perfect molecular mechanisms, cellular signaling pathways, instability and low bioavailability (10).

In the 17th century, Paracelsus said, “All substances are poisons, there is none which is not a poison. It is the dose that distinguishes a poison from a remedy.” A dose that produces a beneficial effect in cell cultures may be poisonous when applied in a human setting. It’s important to note that dosage in an experimental study may or may not be replicated in humans. Numerous factors influence dosage such as the form of a phenolic compound, its bioavailability, and whether or not the flavonoids reach the target site (20).

High-dose polyphenols can potentially cause adverse effects through pro-oxidative effects — risk increased by the use of pharmacological doses of polyphenols in prevention, treatment and dietary supplement situations (19). Thus, the type of safety evaluation would depend on the nature of the polyphenol-containing product (a food, an extract, or a pure compound) and on the proposed use, potentially leading to a significant increase in exposure (20).

As such, risk mitigation takes place by working with experienced advisors and consultants, and executing the requisite safety and efficacy studies at a pre-clinical and clinical setting.

Bonus Note: Cannflavins were analyzed in a computer-aided study that looked at a total of 2750 plant-extracted compounds with biological and pharmacological characteristics and their inhibitory potential against the main protease (Mpro) of COVID-19 – a potent target for developing viral inhibitor drugs toward coronavirus. The study pointed out that compounds with binding activity ranging from -7.8 to -6.5 kcal/mol have enormous potential to be used as inhibitors against the main protease for the recent strain of coronavirus, and cannflavin had a binding activity of -7.1 (18).

Concluding Case for Canurta Inc.

It is reasonable to conclude that Canurta is a company based on good science from which a sound business can be built and exited with considerable value inflection. Our various Canurta ingredient production processes provide inherent advantages over the solutions in the prior art in that they provide various defensible processes that allow the company to commercialize these novel ingredients that nature has provided since antiquity in similar proportions humans and animals are familiar with consuming.

The potent anti-inflammatory properties of the cannflavins and other polyphenols found in hemp were established almost 40 years ago. However, these compounds together have never been formally assayed in any model of disease or injury. This makes Canurta a ground-breaking opportunity, commercially and scientifically. For the first time, there is a promising pathway towards making these novel compounds readily available for the market in their purity for human and animal diets. This can be done affordably for the consumer and with scale. Such findings will advance science and research on hemp polyphenols for pharmaceutical development and make Canurta a high growth venture providing essential solutions that power the next century of global human and animal health and wellness.

Thank you for reading our white paper.

Over the next few months you can look forward to news on our medical advisory committee, our research partners and their findings, and our commercial launches as we continue to scale production of hemp polyphenols and we ready ourselves for 2022 market entry. Please note, I am not a medical doctor and the content in this paper is not medical advice about the use of a product or ingredient produced by Canurta. I am a law school graduate turned entrepreneur because of the opportunity that Canadian legalization presented.

Over the last 4 years I have been using my analytical training, the ability to learn quickly and pick up concepts and large amounts of information, team building experience from my time as a university athlete, along with the grit and ability to just work hard. It’s my love for the job and the opportunity I created that allows me to persevere and execute as the leader of this company. What you have read is how I view this opportunity after studying all the papers I have listed below and more. This is the thesis we base our company on and it is the hook that leads to everything that will come from here and more.

I have attached some testimonials below of our early product testers. We look forward as a company to getting our solutions in the hands of more people that need it as we continue to execute this year.

For more information please contact me at:

Akeem Gardner, LLB CEO & Founder akeem@canurta.com and to learn more www.canurta.com.

All our sources for this review are listed following the testimonials.

The Rules We Played By

Our literature review is based on search strategy examining peer-reviewed literature on cell culture, the bioavailability of polyphenols, prenylated flavonoids, isoprenylated bibenzyls & polyphenols, phenolics, phytochemicals and flavonoids in general.

Journal #

Database Searched

Type of Journal

Journal Reference

1

PubMed

Peer-reviewed

Allegrone G, Pollastro F, Magagnini G, et al. The Bibenzyl Canniprene Inhibits the Production of Pro-Inflammatory Eicosanoids and Selectively Accumulates in Some Hemp sativa Strains. Journal of Natural Products. 2017 Mar; 80(3):731-734. DOI:10.1021/acs.jnatprod.6b01126.

2

ScienceDirect

Peer-reviewed

Barrett, M. L.; Gordon, D.; Evans, F. J. Isolation from Hemp sativa L. of cannflavin-A novel inhibitor of prostaglandin production. Biochem. Pharmacol. 1985, 34, 2019-2024.

3

SpringerLink

Peer-reviewed

Barrett, M. L.; Scutt, A. M.; Evans, F. J.Cannflavin A and B, prenylated flavones from Hemp sativa L. Experientia 1986,42(4), 452-3.

4

SpringerLink

Peer-reviewed

Kennedy DO. Phytochemicals for Improving Aspects of Cognitive Function and Psychological State Potentially Relevant to Sports Performance. Sports Med. 2019 Feb;49 (Suppl 1):39-58. doi: 10.1007/ s40279-018-1007-0. PMID:30671903; PMCID: PMC6445817.

5

PubMed

Peer-reviewed

Izzo, L., Castaldo, L., Narváez, A.,Graziani, G., Gaspari, A., Rodríguez-Carrasco, Y., & Ritieni,A. (2020). Analysis of Phenolic Compounds in Commercial Hemp sativa L.Inflorescences Using UHPLC-Q-Orbitrap HRMS. Molecules (Basel, Switzerland), 25(3), 631.https://doi.org/10.3390/molecules25030631

6

ScienceDirect

Peer-reviewed

Rea, K.A.; Casaretto, J.A.; Al-Abdul-Wahid, M.S.; Sukumaran, A.; Geddes-McAlister, J.; Rothstein, S.J.; Akhtar, T.A. Biosynthesis of cannflavins A and B from Hemp sativa L. Phytochemistry 2019, 164, 162–171.

7

ScienceDirect

Peer-reviewed

Werz O., Seegers J., Schaible A. M., et al. Cannflavins from hemp sprouts, a novel cannabinoid-free hemp food product, target microsomal prostaglandin E2 synthase-1 and 5-lipoxygenase. Pharma Nutrition. 2014; 2(3):53–60. doi:10.1016/j.phanu.2014.05.001

8

PubMed

Peer-reviewed

González-Gallego, J., García-Mediavilla, M., Sánchez-Campos, S., & Tuñón, M.(2010). Fruit polyphenols, immunity and inflammation. British Journal of Nutrition,104(S3), S15-S27. doi:10.1017/ S0007114510003910

9

ScienceDirect

Peer-reviewed

Ibrahim, A. K., Radwan, M. M., Ahmed, S. A., Slade, D., Ross, S. A., El Sohly, M. A., & Khan, I.A. (2010). Microbialmetabolism of cannflavin A and Bisolated from Hemp sativa. Phytochemistry, 71(8-9), 1014 – 1019. https://doi.org/10.1016/j.phytochem.2010.02.011

10

Taylor & Francis Online

Peer-reviewed

Hassan Rasouli, Mohammad Hosein Farzaei & Reza Khodarahmi (2017) Polyphenols and their benefits: Are view, International Journal of FoodProperties, 20:sup2, 1700-1741, DOI:10.1080/10942912.2017.1354017

11

PubMed

Peer-reviewed

Kumar S, Pandey AK. Chemistry and biological activities of flavonoids: an overview. Scientific World Journal. 2013 Dec 29;2013:162750. doi: 10.1155/2013/162750. PMID:24470791;PMCID: PMC3891543.

12

PubMed

Peer-reviewed

Henry-Kirk RA, Plunkett B, Hall M, McGhie T, Allan AC, Wargent JJ, Espley RV. Solar UV light regulates flavonoid metabolism in apple (Malus x domestica). Plant Cell Environ. 2018 Mar;41(3):675-688. doi: 10.1111/pce.13125. Epub 2018 Feb 5. PMID: 29315644.

13

PubMed

Peer-reviewed

Xu Y, Charles MT, Luo Z, Mimee B, Veronneau PY, Rolland D, Roussel D. Preharvest Ultraviolet C Irradiation Increased the Level of Polyphenol Accumulation and Flavonoid Pathway Gene Expression in Strawberry Fruit. J Agric Food Chem. 2017 Nov22;65(46):9970-9979. doi: 10.1021/acs.jafc.7b04252. Epub 2017 Nov 8. PMID:

29091440.

14

Research Gate

Peer-reviewed

Kanthang, S., & Sompornpailin, K. (2013). Increasing Plant Flavonoid Biomaterials in Response to UV-A Light. Advanced Materials Research, 802, 74 - 78.

15

PubMed

Peer-reviewed

Furman, D., Campisi, J., Verdin, E. et al.Chronic inflammation in  the  etiology of disease across the life span. Nat Med 25, 1822–1832 (2019). https://doi.org/10.1038/s41591-019-0675-0

16

ScienceDirect

Peer-reviewed

Simon Erridge, Nagina Mangal, OliverSalazar, Barbara Pacchetti, Mikael H. Sodergren. Cannflavins – Fromplant to patient: A scoping review. Fitoterapia, Volume146,2020, 104712, ISSN 0367-326X. https://doi.org/10.1016/j.fitote.2020.104712.

17

ScienceDirect

Peer-reviewed

Andreas Koeberle, Oliver Werz. Perspective of microsomal prostaglandin E2 synthase-1 as drug target in inflammation-related disorders. Biochemical Pharmacology,Volume 98, Issue 1, 2015. Pages 1-15, ISSN 0006-2952. https://doi.org/10.1016/j.bcp.2015.06.022.

18

SpringerLink

Peer-reviewed

Rasool, N., Akhtar, A. & Hussain, W.Insights into the inhibitory potential ofselective phytochemicals against Mpro of2019-nCoV: a computer-aided study. StructChem 31, 1777–1783 (2020). https://doi.org/10.1007/s11224-020-01536-6

19

ResearchGate

Peer-reviewed

Martin, Keith & Appel, Christy. (2009). Polyphenols as dietary supplements: A double-edged sword. Nutrition andDietary Supplements. 2. 10.2147/NDS.S6422.

20

PubMed

Peer-reviewed

Louise I Mennen, Ron Walker, Catherine Bennetau-Pelissero, Augustin Scalbert, Risks and safety of polyphenol consumption, The American Journal ofClinical Nutrition, Volume 81, Issue 1, January 2005, Pages 326S–329S, https://doi.org/10.1093/ajcn/81.1.326